Sure, there were vampires, witches, and ghosts. But these big-screen stories also got under our skin and gave us something ...

In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...

Truly this is a great bear. An Ursa Major, as former BBC astronomer Patrick Moore might have said. Or, as the kids of today might put it, the new Paddington musical is 'bear lit, bro'. The eagerly ...

Increased global competition has fuelled disruption and competition in almost all industries. There are notable exceptions, however, where businesses are not spoilt for choice. One of those is in the ...

Earlier this year, a woman in Pennsylvania bought a nude charcoal sketch for $12 at a local art auction. Something about the depicted woman’s downward gaze, the hang of flesh around her waist seemed ...

Watch the New York Content Update Trailer for Hotel Architect, a hotel management simulation game developed by Pathos Interactive. Players can now set out to one of the world’s most iconic cities, New ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...

Tempus AI Inc. (NASDAQ:TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said Tempus ...